$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Chief Executive Officer, President & Director
Compensation
$600,000
Chief Financial Officer
Compensation
$411,627
Co-Founder & Chief Operating Officer
Compensation
$675,000
Scientific Founder and Advisor
During the last 12 months, insiders have purchased $1.50M and sold $1.62M worth of ACTU shares, resulting in $124K of net selling activity.
0
0.00
0
0.00
+0
+$0
0
0.00
280.0K
1.62M
-1.6M
-$1.62M
0
0.00
0
0.00
+0
+$0
214.3K
1.50M
0
0.00
+1.5M
+$1.50M
Kreis Leslie W.
Director, 10 Percent Owner:
$500K
Bios Equity Cof, Lp
Director, 10 Percent Owner:
$500K
Fletcher Aaron G.L.
Director, 10 Percent Owner:
$500K
Thomson Todd S
Director, 10 Percent Owner:
$1.62M
Slightly bearish with $124K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
ACTU - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2025 | May 22, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.